NanoViricides Seeks FDA Pediatric Designation for Measles Drug NV-387

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage biopharmaceutical company, has taken a significant step in addressing a critical unmet medical need by filing an application with the U.S. Food and Drug Administration (FDA) for Rare Pediatric Disease Drug designation for its lead drug candidate, NV-387, as a treatment for measles. This filing, which follows a previously submitted orphan drug designation application, positions the company to potentially receive a Priority Review Voucher upon approval—a valuable asset that can accelerate regulatory pathways for other drugs. The move is particularly noteworthy because there are currently no FDA-approved therapies specifically for measles, a highly contagious and sometimes severe viral illness that has seen resurgences in various global regions despite the availability of a vaccine. The company's newsroom at https://ibn.fm/NNVC provides ongoing updates for investors.

NV-387 is described as a unique, broad-spectrum antiviral nanomedicine. The company's development strategy for this drug is expansive, with plans to target respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections. Preclinical data also suggests efficacy in animal models for Monkeypox (MPox), Smallpox, and the aforementioned measles. Importantly, NV-387 has successfully completed a Phase I clinical trial in healthy volunteers with no reported adverse events, and NanoViricides is now focused on advancing the candidate into Phase II human trials. The company's broader pipeline includes another advanced candidate, NV-HHV-1, aimed at treating infections caused by herpesviruses.

The announcement was disseminated through BioMedWire (“BMW”), a specialized communications platform within the Dynamic Brand Portfolio of the InvestorBrandNetwork (IBN). This network leverages a vast array of distribution tools, including wire services, article syndication to over 5,000 outlets, enhanced press release features, and extensive social media reach via IBN, to maximize visibility for companies in the biotechnology and life sciences sectors. By utilizing such a platform, NanoViricides aims to cut through market noise and achieve significant brand recognition among investors, journalists, and the general public. The full press release can be accessed for more details at https://ibn.fm/h9IB4.